NCT06697301ClinicalTrials.gov ↗
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Active, not recruitingPhase IIEN originalBreast cancerGastric cancerTriple negative (TNBC)HER2 positiveMetastatic / advanced
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
NCT06216301ClinicalTrials.gov ↗
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
NCT07700979ClinicalTrials.gov ↗
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
NCT07623174ClinicalTrials.gov ↗
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life. The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth. Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study. The study will look at data already existing in the participants' medical charts.
About the trial
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem histologiczne lub cytologiczne raka żołądka, połączenia żołądka i przełyku lub raka piersi
- •Zaawansowany, nieoperacyjny lub rozsiewny stadium choroby
- •Choroba możliwa do zmierzenia według standardowych kryteriów
- •Ogólny stan zdrowia oceniony na 0 lub 1 w skali ECOG
- •Postęp choroby po standardowym leczeniu lub nietolerancja standardowego leczenia
- •Dla raka piersi HER2-niski: Status HER2-niski (IHC 1+ lub IHC 2+/ISH-ujemny)
- •Dla raka piersi HER2-dodatni: Status HER2-dodatni (IHC 3+ lub IHC 2+/ISH-dodatni)
- •Nie więcej niż 3 poprzednie chemioterapie systemowe (w tym terapie oparte na przeciwciałach)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (135)
Banner-University Medical Center Tucson Campus
Tucson, United States
Banner-University Medical Center Tucson Campus
Tucson, United States
The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal
Tucson, United States
University of Arizona Cancer Center - North Campus
Tucson, United States
The University of Arizona Cancer Center-Main
Tucson, United States
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, United States
UC Irvine Medical Center
Orange, United States
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
San Francisco, United States
UCLA Department of Medicine - Hematology & Oncology
Santa Monica, United States
UCLA Hematology/Oncology - Parkside
Santa Monica, United States
Colorado West Healthcare System, dba Community Hospital
Grand Junction, United States
Colorado West Healthcare, dba Grand Valley Oncology
Grand Junction, United States
Georgetown University Medical Center
Washington D.C., United States
MedStar Georgetown University Hospital
Washington D.C., United States
Moffitt Cancer Center - International Plaza
Tampa, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, United States
Moffitt Cancer Center - McKinley Campus
Tampa, United States
Moffitt McKinley Hospital
Tampa, United States
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, United States
Georgia Cancer Specialists - Athens
Athens, United States
Georgia Cancer Specialists - Annex
Atlanta, United States
Atlanta Cancer Care - Atlanta
Atlanta, United States
Georgia Cancer Specialists-Northside
Atlanta, United States
Northside Hospital, Inc.- Central Research Department
Atlanta, United States
Northside Hospital
Atlanta, United States
Georgia Cancer Specialists - Blairsville
Blairsville, United States
Georgia Cancer Specialists - Canton
Canton, United States
Atlanta Cancer Care - Cumming
Cumming, United States
Georgia Cancer Specialists - Cumming
Cumming, United States
Georgia Cancer Specialists - Decatur
Decatur, United States
Suburban Hematology-Oncology Associates - Duluth
Duluth, United States
Suburban Hematology-Oncology Associates- Lawrenceville
Lawrenceville, United States
Georgia Cancer Specialists - Macon
Macon, United States
Georgia Cancer Specialists - Marietta
Marietta, United States
Memorial Hospital
Shiloh, United States
Siteman Cancer Center - Shiloh
Shiloh, United States
Massachusetts General Hospital.
Boston, United States
Brigham and Women's Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Dana Farber Cancer Institute- Chestnut Hill
Newton, United States
Siteman Cancer Center - St Peters
City of Saint Peters, United States
Siteman Cancer Center - West County
Creve Coeur, United States
Siteman Cancer Center - North County
Florissant, United States
Saint Luke's Cancer Institute LLC
Kansas City, United States
Saint Luke's Hospital Investigational Pharmacy
Kansas City, United States
Barnes-Jewish Hospital
St Louis, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center - South County
St Louis, United States
Renown Regional Medical Center
Reno, United States
Memorial Sloan Kettering Cancer Center - Basking Ridge
Basking Ridge, United States
MSK Basking Ridge
Basking Ridge, United States
Memorial Sloan Kettering - Monmouth
Middletown, United States
MSK Monmouth.
Middletown, United States
Memorial Sloan Kettering - Bergen
Montvale, United States
MSK Bergen.
Montvale, United States
San Juan Oncology Associates
Farmington, United States
Memorial Sloan Kettering Cancer Center - Commack
Commack, United States
MSK Commack.
Commack, United States
Memorial Sloan Kettering - Westchester
Harrison, United States
MSK Westchester.
Harrison, United States
Investigational Drug Service
Long Island City, United States
Memorial Sloan Kettering Cancer Center - Main Hospital
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Memorial Sloan Kettering- Nassau
Uniondale, United States
MSK Nassau.
Uniondale, United States
Zangmeister Cancer Center
Columbus, United States
Saint Francis Hospital / Bon Secours - South Carolina
Greenville, United States
Sarah Cannon Research Institute - Pharmacy
Nashville, United States
SCRI Oncology Partners
Nashville, United States
Tennessee Oncology-Nashville/Sarah Cannon Research Institute
Nashville, United States
Providence Health and Services Washington and Montana
Renton, United States
Harborview Medical Center
Seattle, United States
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington
Seattle, United States
University of Washington Medical Center
Seattle, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, United States
Carbone Cancer Center / University of Wisconsin
Madison, United States
Peninsula & South Eastern Hematology and Oncology Group (PASO)
Frankston, Australia
Slade Pharmacy Frankston
Frankston, Australia
Slade Health
Mount Waverley, Australia
Peninsula & South Eastern Hematology and Oncology Group (PASO)
Frankston, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
BC Cancer Kelowna.
Kelowna, Canada
Ottawa Hospital Cancer Centre
Ottawa, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
University Health Network - Princess Margaret Cancer Centre
Toronto, Canada
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF)
Berlin, Germany
Universitatsklinikum Essen
Essen, Germany
Heidelberg University Hospital and German Cancer Research Center
Heidelberg, Germany
A.O.U. Federico II
Naples, Italy
Azienda Ospedaliera Universitaria (AOU) Federico II
Naples, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale.
Naples, Italy
Istituto Europeo di Oncologia
Milan, Italy
Niguarda Ca' Granda Hospital
Milan, Italy
Humanitas Istituto Clinico Catanese
Misterbianco (CT), Italy
Azienda Ospedaliera Universitaria Integrata di Verona.
Verona, Italy
A.O.U. Federico II- U.O.C. Diagnostica per lmmagini e Radioterapia
Naples, Italy
Cancer Institute Hospital of JFCR
Koto-ku, Japan
Japanese Foundation for Cancer Research
Koto-ku, Japan
Showa University Hospital
Shinagawa-ku, Japan
Okayama University Hospital
Okayama, Japan
Showa Medical University Hospital
Tokyo, Japan
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Dong-A University Hospital
Busan, South Korea
National Cancer Center
Goyang-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Chungbuk National University Hospital
Cheongju-si, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Korea University Anam Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
St. Vincent's Hospital, The Catholic University of Korea
Suwon, South Korea
Quirén Salud Barcelona
Barcelona, Spain
Hospital Universitari Vall d´Hebron
Barcelona, Spain
Institut Catala d'Oncologia
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Grupo Hospitalario QuironSalud
Erandio Bizkaia, Spain
Farmacia-Ensayos. Planta S - Hospital Universitario HM Sanchinarro-CIOCC-START Madrid
Madrid, Spain
START Madrid-CIOCC_Hospital HM Sanchinarro
Madrid, Spain
Ecg Medica Sl
Valencia, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Cancer Center
Taipei, Taiwan
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan
The Royal Marsden Hospital
Sutton, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
St Bartholomew's Hospital
London, United Kingdom
The Royal Marsden Hospital
London, United Kingdom
The Royal Marsden NHS Foundation Trust (RM)
London, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.